Arbutus Biopharma Corporation (ABUS) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Arbutus Biopharma Corporation (ABUS) closed at USD 4.19 on 2026-10-14, a change of -8.5 % over the past year, with a market capitalization of USD 657.55M.
Arbutus Biopharma Corporation recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 4.19 |
| 2026-10-13 | 4.11 |
| 2026-10-12 | 4.15 |
| 2026-10-09 | 4.22 |
| 2026-10-08 | 4.18 |
| 2026-10-07 | 4.29 |
| 2026-10-06 | 4.48 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Arbutus Biopharma Corporation key figures
- Previous close
- USD 4.19 (2026-10-14)
- 1-year change
- -8.5 %
- Market cap
- USD 657.55M
- Enterprise value
- USD 759.77M
- P/E ratio (trailing)
- 5.23
- P/E ratio (forward)
- -25.96
- EPS (trailing)
- 0.82
- EPS (forward)
- -0.17
- PEG ratio
- n/a
- Price to book
- 3.28
- Revenue growth
- -90.6 %
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 5.03
- Employees
- 19
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Arbutus Biopharma Corporation and compare it with other stocks.
Analyze ABUSAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Arbutus Biopharma Corporation shares.